Evidence map›Paper›PMID 32565444›Full record

Trial reportBMJ open respiratory research2020

Intravenous iron and chronic obstructive pulmonary disease: a randomised controlled trial.

Peter Santer, Anne McGahey, Matthew C Frise, Nayia Petousi, Nick P Talbot, Richard Baskerville, Mona Bafadhel, Annabel H Nickol, Peter A Robbins

Open access · goldAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMJ open respiratory research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 3 pooled it
1.6field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Article
  6. Iron and the lung: emerging roles of iron metabolism in pulmonary disease pathogenesis and therapy.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Peter SanterDepartment of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-1735-0774
Anne McGaheyOxford Respiratory Trials Unit, University of Oxford, Oxford, UK.
Matthew C FriseDepartment of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-5575-2531
Nayia PetousiOxford Centre for Respiratory Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Nick P TalbotDepartment of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-9186-8950
Richard BaskervilleNuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK.
Mona BafadhelOxford Centre for Respiratory Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.ORCID http://orcid.org/0000-0002-9993-2478
Annabel H NickolOxford Centre for Respiratory Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
Peter A RobbinsDepartment of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK peter.robbins@dpag.ox.ac.uk.ORCID http://orcid.org/0000-0002-4975-0609
University of Oxford · GBOxford University Hospitals NHS Trust · GB

Funding

British Heart Foundation FS/14/48/30828
6 · The paper itself

Abstract

backgroundIncreased iron availability modifies cardiorespiratory function in healthy volunteers and improves exercise capacity and quality of life in patients with heart failure or pulmonary hypertension. We hypothesised that intravenous iron would produce improvements in oxygenation, exercise capacity and quality of life in patients with chronic obstructive pulmonary disease (COPD).

methodsWe performed a randomised, placebo-controlled, double-blind trial in 48 participants with COPD (mean±SD: age 69±8 years, haemoglobin 144.8±13.2 g/L, ferritin 97.1±70.0 µg/L, transferrin saturation 31.3%±15.2%; GOLD grades II-IV), each of whom received a single dose of intravenous ferric carboxymaltose (FCM; 15 mg/kg bodyweight) or saline placebo. The primary endpoint was peripheral oxygen saturation (SpO

resultsSpO

conclusionsFCM did not improve oxygenation over 8 weeks in patients with COPD. However, this treatment was well tolerated and produced improvements in exercise capacity and functional limitation caused by breathlessness. These effects on secondary endpoints require confirmation in future studies. TRIAL REGISTRATION NUMBER: ISRCTN09143837.

Indexed as

Administration, IntravenousAgedDouble-Blind MethodDyspneaExercise ToleranceFemaleFerric CompoundsHemoglobinsHumansIron DeficienciesMaleMaltoseMiddle AgedOxygenPulmonary Disease, Chronic ObstructiveQuality of Lifeferric carboxymaltoseFerric CompoundsHemoglobinsMaltoseOxygenCOPD pathologyexerciselung physiology

Identifiers

PMID32565444
PMCPMC7311010
OpenAlexW3035328445

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.